Pharmaceutical Business Development

Apr72016 by Pharmaceutical TechNo Comments

Low-Cost Genome Sequencing

BioPharma, Biotechnology, Cheminformatics, Drug Development, Drug Discovery, Economic and Regional Development, Pharma Industry

In Silicon Valley, Moore's law appears to remained on equivalent balance with the regular laws classified by Isaac Newton. Intel prime supporter Gordon Moore's notorious perception that registering power has a tendency to twofold — and that its value hence parts — like clockwork has held valid for about 50 years with just minor update. Yet as a model of quick transform, it is the focus of energetic ill-use from genome analysts. In many presentations over the past few years, researchers have contrasted the slant of Moore's law and the quickly dropping expenses of DNA sequencing. For some time they kept pace, however since something like 2007, it has not even been close. The cost of sequencing a normal human genome has plunged from about Us$10 million to a couple of thousand dollars in only...

Apr42016 by Pharmaceutical TechNo Comments

The Problems with Healthcare Data and How to Manage Them

Pharma Industry, Pharmacetiucal Infotech

People who work with data tend to think in terms which are very structured and linear. They prefer to have B to follow A and C to follow B not just sometimes, but pretty much all of the time. But, healthcare data simply doesn’t work that way. Healthcare data can render linear analysis useless as it is both diverse and complex. There are several characteristics of healthcare data which make it both unique and often difficult to work with. Let’s discuss just a few of those characteristics. Multiple Places Healthcare data tends to be found in a variety of different places. The data tends to come from all over an organisation, from EMRs or human resources software to varying departments such as oncology, radiology or pharmacy. Compiling all of this information into one single central syste...

Mar312016 by Pharmaceutical TechNo Comments

Collaborations are a Secret Boon for the Pharma Industry in India

Economic and Regional Development, Pharma Industry, Pharmaceutical Business Development

After it was recently announced that Bristol-Meyes Squibb and Astra Zenca ended their partnership and Aurobindo Pharma would acquire Dublin-based Actavis, the question on everyone’s minds seems to be, what next? The pharma industry has seen a double-growth in recent times owing to breakthrough patents in the field of cancer drugs and research. Therapies which are closely linked to winter related ailments, have posted strong double digit growths (such as respiratory at over 18.7 per cent, pain or analgesics at over 10.1 per cent), resulting in acute therapies growing faster than chronic segment, for the second consecutive month. For the full year 2013, the pharmaceutical market was reported at Rs 78,644 crore, with a growth of 9.9 per cent, over the same period last year. The Indian mark...

Mar302016 by Pharmaceutical TechNo Comments

Is South Africa Trying to delay Patents on New Medicines?

Economic and Regional Development, Pharma Industry, Pharmaceutical Business Development, Pharmaceutical Distribution and Logistics, Pharmaceutical Patenting

In a recent report by the Guardian, it was revealed that leaked documents showed lobbying proposals to delay laws that would allow fast introduction of generic medicines in South Africa. Shockingly, this means patents on breakthrough (read recently discovered medicine) drugs could be halted, but for what? If the changes to the new intellectual property law take place, this could be a definite reality, warns the Guardian. Drug companies in South Africa have been accused of planning a covert, well-funded campaign to delay the introduction of laws that threaten their profits. Leaked documents show that pharmaceutical companies planned a $450,000 campaign, involving a high-profile consultancy based in Washington, DC, against changes to intellectual property laws that would enable their pat...

Mar272016 by Pharmaceutical TechNo Comments

Glenmark Gives India the Push by Topping its Anti-Diabetes Drug

Pharma Industry, Pharmaceutical Business Development, Pharmaceutical Collaboration

Whatever Glenmark wanted to prove by introducing Zitamed and ZIta, their new anti-diabetes drugs, they’ve definitely topped this season. Mumbai-based Glenmark Pharmaceuticals introduced the two anti-diabetes drugs in aRs 3,000-crore lucrative anti-diabetes market dominated by multinationals The drugmaker, which is locked in a bitter patent infringement battle with US drug firm Merck Sharp and Dohme's (MSD) over these drugs, has managed to rake in Rs 16 crore in just eight months since it launched them, according to data available with All India Organisation of Chemists and Association (AIOCD). In a sort of kickback, Glenmark has priced these drugs at a third of the price of its competitors. Win? We definitely think so. This move may not only rattle the existing market, but also multina...

Mar152016 by Pharmaceutical TechNo Comments

ICT an Aid to the Pharma Sector

Pharma Industry, Pharmacetiucal Infotech

Tremendous pressures exerted from every source for the societal and economic development keep exercising pressures from all around. Governments look forward for the companies from vivid industrial sectors to outperform and raise the scope for employment, GDP contribution and the revenues to the government in form to various taxes. At the same the companies are keen on huge investments in any state, only when the state is in a position of offer them good subsidies, and tax exemptions and infrastructure which can facilitate them with the logistics, human resource skill development, and the key issue of ICT facilitation. In today's scenario, many states are keen on encouraging the investments from pharma companies, and these locations have become a free zone for the companies of small and m...

Mar102016 by Pharmaceutical TechNo Comments

Global Pharma Industry trends

Pharma Industry, Pharmaceutical Business Development

Industry Experts have forecasted a 19 % growth for the Indian Pharmaceutical Industry for the year 2013. Morgan Stanley has said that Investments in research and trade mark expenditure will start bearing fruits in European Union and United States. Several new drugs are expected to be launched as a result of clinical trials and obtaining intellectual property rights. Apart from these, new emerging markets in Japan and other countries will have cascading positive effect in the pharmaceutical industries. Moody's have also forecast return of growth in 2013. They have also said that this status of the market will be stable for another one and half year paving the way for growth and earnings [Outlook report]. This is also based on the expected loss of patent protection of some of the high selli...

Mar52016 by Pharmaceutical TechNo Comments

Future of Pharma Industry – Biotechnology

BioPharma, Biotechnology, Pharma Industry, Pharmaceutical Business Development

Biotechnology can be defined as the use of living systems and organisms to develop or make useful products, or "any technological application that uses biological systems, living organisms or derivatives in order to make or modify products or processes for specific use. However, contrary to its name biotechnology is not a single technology. Rather it is a group of technologies that share two (common) characteristics; working with living cells and their molecules and having a wide range of practice uses that can improve our lives. Traditional biotechnology has been practiced since the beginning of records history. It has been used to enhance the agricultural production, to bake bread, brew alcoholic beverages, and breed food crops or domestic animals. Through early biotechnology, the ear...

Mar22016 by Pharmaceutical TechNo Comments

New challenges for The New Pharmaceutical Industry

Pharma Industry, Pharmaceutical Business Development

The pharmaceutical industry has entered in to a new era in the 21st century for extreme growth and innovations in technology. As there is a technological advancements exists, requirements and challenges are also persists. In pharmaceutical industry for this century, for the key players who are well established in market and intruders to the market have to be prepared to face important challenges and transformations from weak economy and certain financial bumps like price downs and scrutiny on business and ethical practices as well increase in regulation. Few of challenges are like: NCE is the new chemical entity which is most important factor for the pharmaceutical industry and is increasing rapidly with absence of ROI that is return on investment. Whilst, falling in the equity market ca...

Feb292016 by Pharmaceutical TechNo Comments

Hurdles to Global Pharma Markets Growth

Pharma Industry, Pharmaceutical Business Development, Pharmaceutical Excipients and Drug Formulation

One of the premium industrial segments ever and one such industry on which many nations across the globe have relied upon for boosting the economic development is Pharma Industry. However, when we dwell in to the insights, this is one of the most regulated industries and of course it has to be, as it is directly related to the lives of many. The other factor which is tagged to the global pharma markets are the controversies involving the honchos of Pharma sector globally. There are numerous instances where few companies from pharma sector have been in news for one or the other controversies. One way or the other, the global pharma companies had always made news, be it the pricing mechanism, or the issue of handling patents, or the breach of regulations, one or the other issue always is o...